Fig. 4

Role of CFLAR in the treatment of BRCA. A–E Expression of CFLAR in patients who responded to trastuzumab, taxanes, anthracycline, CMF, and FEC. F–G Prognostic value of CFLAR in patients with BRCA treated with tamoxifen. The transcripts of CFLAR were clearly marked on the corresponding data. H Analysis of CCLE data extracted from DepMap revealed that CFLAR expression was correlated with sensitivity to 5-FU. I BT- 549 and MDA-MB- 231 cells were transiently transfected with Flag-CFLAR. J–K Colony formation assay revealed that overexpression of CFLAR increased the inhibitory effects of 5-FU (10 μM) on cell growth. L–M Overexpression of CFLAR resulted in a decrease in ROS levels after 5-FU treatment. Each bar represented the mean ± SD (n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001